About MediGene
MediGene concentrates on researching, developing, and commercializing novel drugs in three therapeutic areas: cancer, autoimmune diseases, and skin diseases. MediGene is the first German biotech company that has drugs on the market an in the approval process. Until now, our drugs are distributed by partner companies. In 2008 we intend to start our own sales activities. MediGene has several drug candidates in clinical development, some of which with an individual annual sales potential exceeding 1 billion €. In addition, we possess innovative platform technologies which enable the search for other therapeutic substances. Licensed products complement our proprietary drug portfolio. This allows us to reduce risks, enhance our opportunities, and excellerate revenue generation.
- Focus : Manufacturer
- Industry : Pharma
Product portfolio of MediGene
News about MediGene
Here you will find MediGene AG
See the theme worlds for related content
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
